证券代码：000999 证券简称：华润三九 投资者关系活动记录表 编号：2024-023 | --- | --- | --- | |--------------|--------------------------|----------------------------------------------------------------------------------| | | | | | | □特定对象调研 | √分析师会议 | | 投资者关系 | □媒体采访 | □业绩说明会 | | 活动类别 | □新闻发布会 | □路演活动 | | | □现场参观 | √其他 | | | | 中信建投、国联证券、中金公司、海通证券、兴业证券、招商证券、天风证券、国信证券、 | | 参与单位名称 | | 中邮证券、申万宏源、中信证券、华创证券、国金证券、浙商证券、国海证券、东北证券、 | | 及人员姓名 | 等证券、投资机构分析师 | 信达证券、华福证券、国盛证券、长江证券、西部证券、中泰证券、东吴证券、华源证券 | | 时间 | 2024 年 10 月 28 日 | | | 地点、方式 | 综合办公中心（电话 ...

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 特别提示： 1、华润三九医药股份有限公司（以下简称"公司"或"华润三九"）于 2024 年 8 月 5 日披露的《华润三九医药股份有限公司重大资产购买预案》（以下简称"本次交易 预案"）及其摘要中已对本次交易涉及的有关风险因素及尚需履行的审批程序进行了详 细说明，公司将根据相关事项的进展情况，及时履行信息披露义务，提请广大投资者关 注后续进展公告并注意投资风险。 股票代码：000999 股票简称：华润三九 编号：2024—116 华润三九医药股份有限公司 关于重大资产重组的进展公告 2、截至本公告披露日，除本次交易预案中披露的有关风险因素外，公司尚未发现 可能导致公司董事会或者交易对方撤销、中止本次重组方案或者对本次重组方案作出实 质性变更的相关事项，本次交易工作正在有序进行中。 特此公告。 一、本次重大资产重组进展情况 华润三九拟以支付现金的方式向天士力生物医药产业集团有限公司（以下简称"天 士力集团"）及其一致行动人天津和悦科技发展合伙企业（有限合伙）（以下简称"天津 和悦"）、天津康顺科技发展合伙企业（有限 ...

感谢大家参加本次会议会议即将开始请稍后 大家好 欢迎参加华润39三级报交流电话会目前所有参会者均处于静音状态下面开始布报 领责声明声明布报完毕后 主持人可直接开始发言 本次会议为中信建投证券股份有限公司中信建投协助上市公司组织的白名单会议仅限受邀嘉宾参会本次会议内容在任何情形下都不构成对会议参加者的投资建议敬请会议参加者充分了解各类投资风险根据自身情况自主做出投资决策并自行承担投资风险 未经中信箭头和演讲嘉宾许可任何机构和个人不得以任何形式将会议内容和相关信息对外公布、转发、转载、传播、复制、编辑、修改等如有上述违法行为中信箭头保留追究相关方法律责任的权利 华人三角的各位领导各位投资人大家晚上好欢迎大家来参加公司三季度业绩交流电话会我是中信建投的医药分析师贺吉尹今天我们非常荣幸的邀请到了公司的董事长邱华伟先生副总裁周辉女士财务总监兼董事会秘书梁珍先生和大家一起来交流公司的三季度的经营情况 和我一起在线主持的还有我们组的分析师刘二飞、袁全和沈欣熙以及来自东北、国联、中京等23家券商的分析师接下来我首先把时间交给公司的董秘梁总请梁总为我们分享一下三季度的经营情况和亮点之后我们也会有一些大家共同关心的问题的一些提问 ...

Investment Rating - The investment rating for the company is "Buy" (maintained) [2][11]. Core Insights - The company reported a revenue of 19.74 billion yuan (+6.08%) and a net profit of 2.96 billion yuan (+23.19%) for the first three quarters of 2024. In Q3 2024, the revenue was 5.63 billion yuan (up 3.16% year-on-year, down 17.29% quarter-on-quarter), with a net profit of 561 million yuan (up 6.85% year-on-year, down 45.73% quarter-on-quarter) [2][3]. Summary by Sections Business Strategy and Performance - The company is focusing on optimizing its business layout, enhancing brand recognition in the CHC sector, and expanding communication with consumers through various media formats. The prescription drug business is being enriched with a focus on product value and competitiveness, while the national medicine business is solidifying its foundational operations [3]. - The company is also pursuing strategic acquisitions, including a planned acquisition of 28% of Tian Shi Li, which will enhance collaboration in areas such as herbal material cultivation and innovative research [3]. Financial Metrics - For the first three quarters of 2024, the company achieved a gross margin of 52.68% (up 0.89 percentage points year-on-year) and a net margin of 16.44% (up 1.96 percentage points year-on-year). The comprehensive gross margin for Q3 2024 was 50.47% (down 0.29 percentage points year-on-year, down 3.25 percentage points quarter-on-quarter) [4][7]. - The company’s total expenses as a percentage of revenue decreased by 1.66 percentage points year-on-year, with sales, management, and financial expense ratios at 24.07%, 5.44%, and -0.07%, respectively [4]. Earnings Forecast - The earnings forecast for the company has been adjusted, with expected net profits of 3.37 billion yuan, 3.82 billion yuan, and 4.23 billion yuan for 2024, 2025, and 2026, respectively. The corresponding EPS is projected to be 2.62 yuan, 2.97 yuan, and 3.29 yuan [7][9].

来源：公司年报、国金证券研究所 持续提升品牌影响力,并购整合工作稳步推 医药组 分析师： 袁维（执业 S1130518080002） yuan_wei@gizq.com.cn 市价(人民币):47.44元 相关报告: 永 实发员三届》, 2024.8.25 永 实发网三九公司点评：业绩增长凸显强韧性，内生外延 2. 《华润三九公司点评：.8.8 合巩固公司行...对，2024.8.8.8 2024.3.23 0 200 400 600 800 1,000 1,200 1,400 1,600 30.00 34.00 38.00 42.00 46.00 50.00 54.00 231027231127231227240127240227240327240427240527240627240727240827240927 人民币(元) 成交金额(百万元) 成交金额 华润三九 沪深300 | --- | --- | --- | --- | --- | --- | |-------------------------------|--------|--------|--------|--------|--------| ...

Investment Rating - The investment rating for the company is maintained as "Buy" [1][3]. Core Views - The company's Q3 2024 performance met expectations, with revenue of 19.74 billion (up 6.08% YoY) and net profit of 2.96 billion (up 23.19% YoY) [1]. - The core CHC health consumer products business is experiencing good growth, supported by brand reputation and strategic marketing efforts [1]. - The company is actively pursuing strategic mergers and acquisitions, including a controlling stake in Tian Shili and the integration with Kun Pharmaceutical Group, aiming for synergistic growth in traditional Chinese medicine and high-quality development [1]. - The company expects a steady increase in net profit for 2024-2026, with projected figures of 3.43 billion, 3.91 billion, and 4.47 billion respectively, reflecting a growth rate of 20.05%, 14.19%, and 14.30% [1][2]. Financial Summary - For Q3 2024, the company reported a revenue of 5.63 billion (up 3.16% YoY) and a net profit of 561 million (up 6.85% YoY) [1]. - The gross margin for the core business in Q3 2024 was 55.53%, an increase of 1.95 percentage points YoY, attributed to a higher proportion of high-margin products [1]. - The company’s operating expenses increased due to enhanced brand building and R&D investments, with sales, management, and R&D expense ratios at 26.73%, 7.67%, and 4.39% respectively [1]. - The projected revenue for 2024 is 26.31 billion, with a growth rate of 6.37% [2].

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 华润三九医药股份有限公司（以下简称"公司"）董事会 2024 年第二十次会议审议通过 了《关于召开 2024 年第六次临时股东大会的议案》，公司定于 2024 年 11 月 11 日（星期一） 召开 2024 年第六次临时股东大会，现将本次会议有关事项通知如下： 一、召开会议的基本情况 股票代码：000999 股票简称：华润三九 编号：2024—112 华润三九医药股份有限公司 关于召开 2024 年第六次临时股东大会通知 1．股东大会届次：2024 年第六次临时股东大会 2．召集人：华润三九医药股份有限公司第九届董事会 3．本次股东大会会议召开符合有关法律、行政法规、部门规章、规范性文件和《公司 章程》的规定。本次股东大会由公司第九届董事会 2024 年第二十次会议决定召开。 4．会议召开的日期、时间： 现场会议：2024 年 11 月 11 日下午 14:30 网络投票时间：2024 年 11 月 11 日。其中，通过深圳证券交易所交易系统投票的时间为 2024 年 11 月 11 日上午 9:15—9:25 ...

Financial Performance - Revenue for the third quarter was RMB 5.634 billion, a year-on-year increase of 3.16%[2] - Net profit attributable to shareholders of the listed company for the third quarter was RMB 561.47 million, a year-on-year increase of 6.85%[2] - Total revenue from the beginning of the year to the end of the reporting period was RMB 19.74 billion, a year-on-year increase of 6.08%[2] - Net profit attributable to shareholders of the listed company from the beginning of the year to the end of the reporting period was RMB 2.96 billion, a year-on-year increase of 23.19%[2] - Basic earnings per share for the third quarter were RMB 0.44, a year-on-year increase of 7.32%[2] - Total revenue for the period reached 19.74 billion yuan, an increase from 18.61 billion yuan in the previous year[19] - Net profit attributable to parent company shareholders was 2.96 billion yuan, up from 2.40 billion yuan in the same period last year[20] - Basic earnings per share increased to 2.32 yuan from 1.88 yuan in the previous year[20] - Operating profit grew to 3.89 billion yuan from 3.25 billion yuan in the previous year[20] - Total comprehensive income for the period was 3.24 billion yuan, compared to 2.70 billion yuan in the prior year[20] - Minority interest in net profit was 284.88 million yuan, slightly down from 292.58 million yuan[20] Assets and Liabilities - Total assets at the end of the reporting period were RMB 40.77 billion, an increase of 1.55% compared to the end of the previous year[2] - Equity attributable to shareholders of the listed company at the end of the reporting period was RMB 20.53 billion, an increase of 8.25% compared to the end of the previous year[2] - Total liabilities decreased to 14.71 billion yuan from 15.89 billion yuan[18] - Total equity increased to 26.06 billion yuan from 24.26 billion yuan[18] - Total assets increased to 40.77 billion yuan from 40.15 billion yuan[18] Cash Flow - Investment activities cash inflow increased by 119.50% to 4.25 billion yuan, mainly due to increased redemption of financial products[5] - Investment activities cash outflow surged by 277.59% to 6.34 billion yuan, primarily driven by increased purchase of financial products[5] - Cash and cash equivalents decreased by 818.32 million yuan, a 121.74% drop, mainly due to increased net cash outflows from investment and financing activities[6] - Sales of goods and services received cash of 19.9 billion yuan, a slight decrease from 20.15 billion yuan in the same period last year[21] - Net cash flow from operating activities increased to 3.2 billion yuan, up from 3.05 billion yuan in the previous year[21] - Cash received from investment returns was 51.47 million yuan, more than double the 23.87 million yuan from the previous year[21] - Cash outflow for investments surged to 5.71 billion yuan, significantly higher than 1.07 billion yuan in the same period last year[21] - Net cash flow from financing activities was negative 1.93 billion yuan, compared to a positive 451.63 million yuan in the previous year[21] - The company's cash and cash equivalents at the end of the period stood at 5.4 billion yuan, down from 6.22 billion yuan at the beginning of the period[21] Investments and Acquisitions - Long-term equity investments increased by 208.59% to RMB 445.11 million, mainly due to the company's increased stake in Runsheng Pharmaceutical[4] - Other non-current financial assets decreased by 43.16% to RMB 243.92 million, also due to the increased stake in Runsheng Pharmaceutical[4] - The company plans to acquire 28% of Tianjin Tasly Pharmaceutical Group Co., Ltd. (Tasly) for a total transaction value of 6,211,844,129.70 RMB, involving 418,306,002 shares[10] - The acquisition of Tasly aims to enhance the company's innovation capabilities in traditional Chinese medicine (TCM) and strengthen its competitive advantage in the TCM industry chain[10] - The company plans to acquire 28% of Tianjin Tianshi Pharmaceutical Group Co., Ltd. (Tianshi) for a total transaction value of 6,211,844,129.70 RMB[14] R&D and Innovation - The company is advancing multiple R&D projects, including CR999C1905L1 (Phase I clinical trial for anti-tumor) and CR999K1601L1 (Phase III clinical trial for gastric cancer)[9] - R&D expenses rose to 512.18 million yuan from 458.44 million yuan, reflecting increased investment in innovation[19] Brand and Market Position - The company's 999 cold medicine brand has established a strong reputation, contributing to the growth of the respiratory product category[8] - The company's formula granule business achieved restorative growth by seizing market opportunities and responding to regional volume-based procurement[8] - Kunming Pharmaceutical Group launched a brand culture promotional video titled "Asking the Way 1381" to strengthen its historical and brand positioning in the premium TCM market[10] - The company's 777 brand continues to promote the awareness of Panax notoginseng saponins through nationwide events and campaigns targeting vascular health[10] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period is 42,272[11] - Huarun Pharmaceutical Holdings Co., Ltd. holds 63.02% of the company's shares, making it the largest shareholder[11] - Hong Kong Securities Clearing Company Limited holds 5.11% of the company's shares, representing 65,655,105 shares[11] - China Europe Healthcare Hybrid Securities Investment Fund holds 3.28% of the company's shares, representing 42,063,791 shares[11] - The top 10 shareholders do not have any restricted shares, and there are no share pledges, marks, or freezes reported[11] Impairment and Losses - Credit impairment losses increased by 134.98% to 100.30 million yuan, mainly due to increased receivables impairment[5] - Asset impairment losses rose by 42.05% to 110.90 million yuan, primarily due to increased inventory impairment[5] Organizational Changes - Kunming Pharmaceutical Group is undergoing organizational restructuring to improve efficiency and integration, focusing on strategic leadership and business empowerment[10] Financial Assets and Liabilities - The company's monetary funds decreased from 6,770,772,624.49 RMB at the beginning of the period to 6,142,655,627.85 RMB at the end of the period[16] - The company's trading financial assets increased from 1,456,014,376.60 RMB at the beginning of the period to 2,703,982,900.00 RMB at the end of the period[16] - The company's accounts receivable increased from 6,182,207,129.31 RMB at the beginning of the period to 6,441,047,110.47 RMB at the end of the period[16] - The company's prepayments increased from 495,693,028.73 RMB at the beginning of the period to 655,095,463.49 RMB at the end of the period[16] - The company's long-term equity investments increased from 144,236,253.72 RMB at the beginning of the period to 445,105,356.27 RMB at the end of the period[17] - The company's fixed assets decreased from 5,889,586,843.63 RMB at the beginning of the period to 5,708,412,059.83 RMB at the end of the period[17] - The company's short-term borrowings decreased from 885,650,677.42 RMB at the beginning of the period to 821,609,434.11 RMB at the end of the period[17] - The company's contract liabilities decreased from 1,650,152,413.83 RMB at the beginning of the period to 1,461,449,573.53 RMB at the end of the period[17] - The company's long-term borrowings decreased from 1,802,931,971.57 RMB at the beginning of the period to 1,382,085,703.21 RMB at the end of the period[17] Audit Information - The third quarter report was not audited[22]

股票代码：000999 股票简称：华润三九 编号：2024—110 华润三九医药股份有限公司 2024 年第十四次监事会会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 华润三九医药股份有限公司（以下简称"公司"或"华润三九"）监事会 2024 年第 十四次会议于 2024 年 10 月 25 日在华润三九医药工业园综合办公中心 105 会议室召开。 会议通知以书面方式于 2024 年 10 月 15 日发出。会议由监事会主席陶然先生主持，本 次会议应到监事 5 人，实到监事 5 人。本次会议的召开及程序符合《公司法》和《公司 章程》的规定，会议合法有效。会议以投票方式审议通过了以下议案，并形成决议： 一、关于公司 2024 年第三季度报告的议案 华润三九医药股份有限公司（以下简称"公司"）监事会对公司 2024 年第三季度报 告发表审核意见如下： 1、公司 2024 年第三季度报告的编制和审议程序符合法律、法规和公司章程的规定； 2、公司 2024 年第三季度报告的内容和格式符合中国证监会和深圳证券交易所的各 项规定，所记载的信息真实地反映出公司 ...

股票代码：000999 股票简称：华润三九 编号：2024—109 华润三九医药股份有限公司 2024 年第二十次董事会会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 华润三九医药股份有限公司（以下简称"公司"或"华润三九"）董事会 2024 年 第二十次会议于 2024 年 10 月 25 日在华润三九医药工业园综合办公中心 105 会议室召 开。会议通知以书面方式于 2024 年 10 月 15 日发出。本次会议应到董事 11 人，实到董 事 10 人，原董事杨旭东先生已辞去公司董事职务，不再出席公司董事会会议。本次会 议由公司董事长邱华伟先生主持，公司监事会成员和部分高级管理人员列席会议。本次 会议的召开及程序符合《公司法》和《公司章程》的规定，会议合法有效。会议以投票 方式审议通过了以下议案，并形成决议： 二、 关于公司 2024 年前三季度利润分配预案的议案 为深入响应《国务院关于加强监管防范风险推动资本市场高质量发展的若干意见》 （国发〔2024〕10 号）文件精神和相关要求，推动一年多次分红、预分红、春节前分 红，增加分红频次、前置 ...